Erste Asset Management GmbH Sells 240,000 Shares of Guardant Health, Inc. (NASDAQ:GH)

Erste Asset Management GmbH decreased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 25.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 692,600 shares of the company’s stock after selling 240,000 shares during the quarter. Erste Asset Management GmbH’s holdings in Guardant Health were worth $21,144,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Guardant Health in the 4th quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Guardant Health in the 3rd quarter valued at about $34,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the 4th quarter valued at about $43,000. Jones Financial Companies Lllp raised its holdings in shares of Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after buying an additional 817 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Guardant Health by 47.4% during the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock valued at $88,000 after buying an additional 929 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Piper Sandler raised their price objective on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Guggenheim reissued a “buy” rating and set a $56.00 price objective on shares of Guardant Health in a report on Monday, February 24th. Canaccord Genuity Group raised their price objective on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 24th. Finally, Raymond James reissued an “outperform” rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $48.40.

Insider Activity at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares in the company, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 2,668 shares of company stock worth $95,208 over the last ninety days. 5.50% of the stock is owned by corporate insiders.

Guardant Health Stock Up 1.1 %

NASDAQ GH opened at $43.10 on Thursday. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89. The firm has a market capitalization of $5.32 billion, a PE ratio of -12.11 and a beta of 1.50. The stock’s 50 day moving average is $42.40 and its 200 day moving average is $32.61.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. On average, research analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.